DIA 2027

Every breakthrough starts with a conversation. Every connection creates new opportunities. Every year, the Global Annual Meeting brings together the people shaping what's next.

See More Photos

Click to expand

San Diego, CA · June 2027

Advancing the field together

Where Possibility Becomes Progress.

DIA Global Annual Meeting brings together the people discovering, developing, regulating, funding, and advancing healthcare innovation.

Because the challenges shaping healthcare don't fit neatly into a single discipline, neither does the conversation.

Redefining Scientific Possibility

Explore breakthroughs in clinical research, personalized medicine, emerging technologies, and medical product development.
Redefining Strategic Possibility

Understand the market forces, regulatory developments, and leadership decisions shaping the future.
Redefining Operational Possibility

Learn how organizations are navigating complexity, improving execution, and accelerating impact.
Redefining Human Possibility

Bring patient perspectives, lived experience, and community voices into the conversations that matter most.

Explore Our Tracks

Hear From Our Community

What Attendees Say

Discover how DIA's Global Annual Meeting has transformed careers, sparked collaborations, and advanced the life sciences community year after year.

I got involved with DIA about 20 years ago, and I started being a member to join the Global Annual Meeting and also the meeting in Europe. I really enjoyed that.

Since then, I became the co-chair of the DIA Regulatory Policy Community, and I love the fact to bridge the community at DIA with the Global Meeting and make sure we have the regulators, the policy makers, the patients, industry members, academia, and have meaningful conversations to push some of these topics forward and get more medicines to patients faster.

Elizabeth Lange

Vice President & Head, RQC, Science, Policy & Intelligence (SPI), Novo Nordisk A/S

I think I really look forward to some of the conversation in terms of how we use AI in drug development, but really starting to discuss how do we go beyond the hype, because it's been out there for a while, everybody's excited about it, but I think what we still have to see is the actual ability to scale that up and to see the actual return investments on the use of AI for drug development.

And again, I think the Global Annual Meeting is a really good place to share some use case, to really ask the question — is that really adding value? What are the risks? And how do we all work as an ecosystem to regulate it in a way that it doesn't prevent innovation?

Dr. Timothe Menard

Global Head of Quality Excellence Digital, Roche — Basel, Switzerland

I'm really excited to see conversations take shape at DIA this year about the intersection between medical devices, diagnostics, and drugs — and how regulators and industry and other stakeholders will be coming together to talk about the current challenges we face in developing personalized medicines and the diagnostics that are needed to accompany them.

Really excited to work with all of the parties together at DIA on those issues.

Megan Doyle

Associate Vice President, Assistant General Counsel – Diagnostics, Eli Lilly and Company

Our commitment to you

Redefining What's Possible for Every Audience.

Whatever brings you to San Diego, whether it's your first Global Annual Meeting or your tenth, every track, session, and conversation is designed to move your work forward.

Years of DIA
excellence

🚀 Accelerators Investors · BD Leaders · CRO Partners
Redefining Innovation Possibility Discover emerging technologies, investment opportunities, new business models, and partnerships shaping the future of healthcare.
Explore your experience →
🔬 Builders Scientists · Clinical Researchers · R&D
Redefining Scientific Possibility Connect science, technology, regulation, and patient need to accelerate the journey from discovery to impact.
Explore your experience →
🤝 Connectors Patients · Advocates · Medical Societies
Redefining Human Possibility Ensure patient voices, community perspectives, and lived experiences shape the future of healthcare.
Explore your experience →
🏛️ Decision Makers C-Suite · SVPs · Senior Directors
Redefining Strategic Possibility Gain the insight, connections, and foresight needed to lead through disruption and drive transformation.
Explore your experience →
⚙️ Operators Clinical Operations · Regulatory Affairs · Quality Assurance & Compliance
Redefining Operational Possibility Navigate increasing complexity with practical solutions, new approaches, and peer-driven learning.
Explore your experience →

Got questions?

Frequently asked questions

Who should attend DIA 2027 Global Annual Meeting?

DIA 2027 Global Annual Meeting is designed for professionals across the full lifecycle of drug development — regulatory affairs, clinical operations, medical affairs, market access, digital health, and more. Whether you are an early-career professional or a C-suite executive, there is a tailored pathway for you.

When and where is DIA 2027 Global Annual Meeting?

DIA 2027 Global Annual Meeting will be held June 28 – July 01, 2027 in San Diego, CA at the San Diego Convention Center.

What are the registration rate categories?

Registration is available at Member and Non-Member rates across Industry and Academic/Government tiers. Pre-Sale and Early Bird rates offer the deepest discounts. Group registration options are also available for teams of five or more.

How do I become a DIA member?

DIA membership provides year-round access to educational content, discounted conference registration, and a global professional network. Visit the DIA Membership page to explore individual and organizational membership options.

Are pre-conference short courses available?

Yes — DIA offers a range of pre-conference short courses and workshops on specialized topics. These half-day and full-day sessions require separate registration and are designed to provide in-depth, practical training.
Short Courses are available for purchase as an add-on to your registration.

How do I submit a topic or an abstract proposal?

DIA accepts topics first then abstracts through a structured submission process. Visit our Get Involved page for submission guidelines, deadlines, and topic priorities once the call for submissions is open.

Have more questions? Visit our full FAQ page for comprehensive answers.

View all FAQs

Your next step

What Will You Redefine?

Join the scientists, regulators, innovators, leaders, operators, and patient advocates shaping the future of healthcare and life sciences.

4,000+

Attendees

175+

Sessions

40+

Countries

Comité del programa

Linda Akunne, MPH • Chief, Project Management Staff, ORO, OND, CDER
FDA, United States
Karthik Balasubramanian, PhD, MS • Dir Project/Program Management, External Manufacturing
Teva Pharmaceuticals, United States
Amy Bertha • Executive Director, Regulatory Policy and Science
Bayer, United States
Asia Blackwell • Consumer Safety Officer, CBER
FDA, United States
James Buchanan, PharmD • President
Covilance LLC, United States
Mandy Kaur Budwal-Jagait, MSc • Interim Deputy Director Standards and Compliance
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Magda Bujar • Associate Director, Regulatory Programme and Strategic Partnerships
Centre for Innovation in Regulatory Science (CIRS), United Kingdom
Ramona Burress, PharmD • Board Member
Onyx Health Collective, United States
Brooke Casselberry, MS, RAC • Vice President, Advisory and Delivery
Epista Life Science, United States
Nina S. Cauchon, PhD • Director Regulatory Affairs CMC
Amgen, United States
Meghana Chalasani, MHA • Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
FDA, United States
Joan Chambers • Independent Senior Consultant
Tufts Center for the Study of Drug Development, United States
Wendy Charles, PhD • Associate Professor
University of Colorado Denver, United States
Rachel Chasse, MS • Associate Director, Digital Science Strategy
AbbVie, United States
Monica Chiaramonte, PhD • Director, Clinical Regulatory Writing
AstraZeneca, United States
Christine Colvis, PhD • Director, Drug Development Partnership Programs
National Center for Advancing Translational Sciences (NCATS), United States
Karen Correa, PhD • Vice President, Clinical Development Operations
Boehringer Ingelheim, United States
Stephanie Crawford, PhD, MPH, MS • Professor Emerita - Pharmacy Systems, Outcomes and Policy
University of Illinois Chicago Retzky College of Pharmacy, United States
Alysha Croker • Director, Strategic and Horizontal Policy
Health Canada, Canada
Matthew Curin, PharmD • Sr. Dir, Head of Program Management, Therapeutic Dermatology
Galderma, United States
Nicholas Daniel, PharmD, MS • Regulatory Officer, OND, CDER
FDA, United States
Paul Dearden • Head, Global Regulatory Policy
Biogen, United Kingdom
Victoria DiBiaso, BSN, MPH, RN • Head of Patient Driven Medicines Development, R&D
Sanofi, France
Joseph Dustin • Senior Director Digital Clincal Development
Sanofi, United States
Wyatt Gotbetter, MPA • President, Market Access
Fingerpaint Group, United States
Courtney Granville, PhD, MPH •
United States
Lani Hashimoto • Consultant, Patient Experience
Hashimoto Consulting Services, United States
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands
Stacy Holdsworth, PharmD • US Regulatory Policy & Strategy Consultant
Holdsworth Solutions LLC, United States
Cammilla Horta Gomes, MA • Latam Regulatory Policy Lead
Roche, Brazil
Huong Huynh, PhD • Director of Regulatory Science
Critical Path Institute, United States
Sarah Jarvis, MBA • Global Medical & Evidence Lead
ZS Associates, United States
Angelika Joos, MPharm • Consultant
Consultant, Belgium
Kimberley Kallsen, PhD, MPH • Head of Patient & Site Engagement, Global Clinical Development Operations
Boehringer Ingelheim, Germany
Yatika Kohli, MBA • Chief Compliance and Strategy Officer
NoNO Inc, Canada
Dominique Lagrave, PharmD • Chief Regulatory Officer
Accumulus Technologies, United States
Elizabeth Lange, MPH, MS • Vice President
Novo Nordisk A/S, United States
Charles Lee, MBA, MS • Executive Regulatory Science Director
AstraZeneca, United States
Jong-Hoon Lee, MD • Senior Physician, OC, CDER
FDA, United States
Demetra Macheras, MBA •
United States
Sarah Martin, MS • Senior Director - Global Regulatory Policy (U.S.A. & LATAM)
Eli Lilly and Company, United States
Lindsay McNair, MD, MPH, MS • Principal Consultant
Equipoise Consulting, United States
Pallavi Mishra-Kalyani, PhD, MS • Deputy Division Director, DBV, OB, CDER
FDA, United States
May F Mo, MBA, MS • Associate Vice President, Biostatistics
Amgen, United States
Monica Munoz, PharmD, PhD • Division Director, Pharmacovigilance-I, OSE, CDER
FDA, United States
Y. Veronica Pei, MD, MPH • Deputy Division Director
FDA, United States
Vada A. Perkins, DVM, MSc, MSN • Vice President, Global Head of Regulatory Intelligence & Policy
Boehringer Ingelheim, United States
Regina Lynn Preciado • VP, Content Strategy Solutions
Content Rules, Inc., United States
Amanda Roache, MS • Deputy Vice President, Science and Regulatory Advocacy
PhRMA, United States
Anjali Shah, PharmD • Executive Director, Business Capabilities and Innovation, WWPS
United States
Cary Smithson, MBA • Managing Partner and Owner
LeapAhead Solutions, Inc., United States
Elizabeth Somers, MS • Associate Vice President, Global Project and Alliance Management
Merck & Co., Inc., United States
Benjamin Stevens, MPH • Senior Director, Regulatory Affairs CMC Policy and Advocacy
Alnylam Pharmaceuticals, United States
Ling Su, PhD • Research Fellow
Yeehong Business School, China
John Z. Sun, MBA, PMP • Program Lead, Portfolio, Strategy & Operations, CRM DU, Development
Novartis, United States
Michael Torok, PhD • Vice President, Global Head of Quality Assurance Programs
Genentech, A Member of the Roche Group, United States
Nicole Turner • Head, Study Optimization
Daiichi Sankyo, United States
Yoshiaki Uyama, PhD, MS, RPh • Executive Director, Regulatory Science Center
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Pujita Vaidya, MPH • Director, Regulatory Science and Policy
Sanofi, United States
James Valentine, JD, MHS • Director
Hyman, Phelps & McNamara, PC, United States
Sarah Vaughan • Head of Vigilance Operations
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
James Wabby, MHS • VP, Head of Regulatory Strategy, Emerging Technologies and Combination Products
AbbVie, United States
Larisa Wu, PhD, MS • Chemist, ONDP, OPQ, CDER
FDA, United States
Amira Deia Younes • Director- Europe, Middle East & Africa (EMEA), Science & Regulatory Policy
MSD, United Arab Emirates